REDUCE-IT: Fewer Procedures Alone Points to Vascepa Benefit

]]>(MedPage Today) -- Patients receiving icosapent ethyl (Vascepa) in the REDUCE-IT trial were one-third less likely to need revascularization during 5 years of follow-up than the placebo group, according to a prespecified secondary analysis.Rates...